Posted by Michael Wonder on 07 Jul 2020
Senhwa Biosciences's silmitasertib receives rare paediatric disease designation from U.S. FDA for treatment of recurrent sonic hedgehog medulloblastoma
7 July 2020 - Senhwa Biosciences today announced that the U.S. FDA granted rare paediatric disease designation for its drug silmitasertib, a casein kinase 2 inhibitor, being developed as a treatment for recurrent sonic hedgehog medulloblastoma.
With the designation, Senhwa Biosciences is eligible for a priority review voucher which can be used for a subsequent marketing application, and may be sold or transferred.
